Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PHARMACEUTICALS INC / MA

Form 4 April 29, 2015

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

response...

burden hours per

Check this box if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Kearney Terrence C

2. Issuer Name and Ticker or Trading

Symbol

5. Relationship of Reporting Person(s) to Issuer

VERTEX PHARMACEUTICALS INC / MA [VRTX]

3. Date of Earliest Transaction

(Check all applicable)

(Last) (First) (Middle)

(Month/Day/Year) 04/27/2015

_X__ Director 10% Owner Other (specify Officer (give title

C/O VERTEX **PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE**

(State)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

BOSTON, MA 02210

(City)

(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. 4. Securities Acquired (A) Transactiomr Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8) (A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/27/2015		Code V M	Amount 28,125	(D)	Price \$ 56.99	28,125	D	
Common Stock	04/27/2015		M	20,000	A	\$ 53.85	48,125	D	
Common Stock	04/27/2015		M	20,000	A	\$ 59.55	68,125	D	
Common Stock	04/27/2015		S <u>(1)</u>	26,593	D	\$ 127.5 (2) (3)	41,532	D	

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Common Stock	04/27/2015	S <u>(1)</u>	16,295	D	\$ 128.12 (3) (4)	25,237	D
Common Stock	04/27/2015	S <u>(1)</u>	4,500	D	\$ 129.94 (3) (5)	20,737	D
Common Stock	04/27/2015	S(1)	8,800	D	\$ 130.58 (3) (6)	11,937	D
Common Stock	04/27/2015	S(1)	3,969	D	\$ 131.76 (3) (7)	7,968	D
Common Stock	04/27/2015	S(1)	5,668	D	\$ 132.82 (3) (8)	2,300	D
Common Stock	04/27/2015	S <u>(1)</u>	2,300	D	\$ 133.63 (3) (9)	0	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of Transactio Derivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 56.99	04/27/2015		M	28,125	(10)	05/16/2021	Common Stock	28,125
Stock Option (right to buy)	\$ 53.85	04/27/2015		M	20,000	<u>(11)</u>	05/31/2021	Common Stock	20,000

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Stock

Option (right to buy)

\$ 59.55 04/27/2015

M

X

20,000

(11)

05/31/2022 Common

Stock 20,000

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Kearney Terrence C C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210

Signatures

Omar White, Attorney-In-Fact

04/29/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$127.50 (range \$126.87 to \$127.86).
- (3) Mr. Kearney undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$128.12 (range \$127.87 to \$128.83).
- (5) Open market sales reported on this line occurred at a weighted average price of \$129.94 (range \$129.16 to \$130.15).
- (6) Open market sales reported on this line occurred at a weighted average price of \$130.58 (range \$130.16 to \$131.14).
- (7) Open market sales reported on this line occurred at a weighted average price of \$131.76 (range \$131.25 to \$132.20).
- (8) Open market sales reported on this line occurred at a weighted average price of \$132.82 (range \$132.32 to \$133.30).
- (9) Open market sales reported on this line occurred at a weighted average price of \$133.63 (range \$133.36 to \$134.09).
- (10) The option vests in 16 quarterly installments from 05/17/2011.
- (11) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3